SeaStar Medical completed a business combination with LMF Acquisition Opportunities (NASDAQ:LMAO), a special purpose acquisition company sponsored by LM Funding America (NASDAQ:LMFA).
The combined company was renamed SeaStar Medical Holding and will operate with SeaStar’s management team, which is led by Eric Schlorff, CEO. Caryl Baron will serve as interim CFO.
The common stock and warrants of SeaStar Medical Holding are expected to begin trading on NASDAQ on October 31, under the new ticker symbols, ICU and ICUCW, respectively.
“This transaction provides us greater resources to advance our Selective Cytopheretic Device (SCD) for patients suffering from the devastating consequences of hyperinflammation,” Mr. Schlorff said in a statement.
“We have submitted our humanitarian device exemption application to the FDA for pediatric use, and we plan to launch a pivotal study of the SCD in adults with acute kidney injury in the first quarter of 2023. As a public company, we will be better positioned to move these programs forward.”
Maxim Group LLC served as sole financial advisor to SeaStar Medical in connection with the business combination.
